This new immunotherapy trial that has an arm that appears to be open to all subtypes of CRC.
The target is a different checkpoint inhibitor target than PD-1 called "VISTA". This is the first anti-VISTA drug to enter clinical trials. It's code name is "JNJ-61610588" and the clinical trial is NCT02671955. It looks like they will have (4) trial site for now: NY, TN, NC, PA.
I also linked a preclinical review of VISTA where they focused on lung cancer and CRC.
This is a monotherapy trial - I suspect its activity could be highest as a combo with PD-1 but as the very first VISTA inhibitor to enter clinical trials - we are all learning together. It is interesting that they have not planned a PD-1 combo expansion arm..... could be for efficacy reasons or safety reasons or some other reason - hard to know...
Immunotherapy science marches on!